|
||
|
Pentz, RD, Billot L, Wendler D. Research on Stored Biological Samples: Views of African American and White American Cancer Patients. American Journal of Medical Genetics. 2006:140A:733-739. Han S , Khuri FR , Roman J . Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Research.66(1): 315-23, 2006 Zou W, Yue P, Lin N, He M, Zhou Z, Lonial S, Khuri FR, Wang B, Sun SY. Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clinical Cancer Research. 12(1): 273-80, 2006 Du Y, Masters SC, Khuri FR, Fu H. Monitoring 14-3-3 protein interactions with a homogeneous fluorescence polarization assay. Journal of Biomolecular Screening, 11(3):269-76, 2006. Khuri FR , Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong WK. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. Journal of the National Cancer Institute 98(7), 441-450, 2006. Yue P, Zhou Z, Khuri FR, Sun SY.Depletion of intracellular glutathione contributes to JNK-mediated death receptor 5 upregulation and apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me). Cancer Biology and Therapy. 5(5) [Epub ahead of print] 2006. Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK, Lee HY. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clinical Cancer Research. 12(2):653-61, 2006 Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA Jr, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittelman WN, Hong WK, Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. Clinical Cancer Research. 12(10): 3109-3114, 2006. Porter GW , Khuri FR , Fu H . Dynamic 14-3-3/client protein interactions integrate survival and apoptotic pathways. Semin Cancer Biol . 2006 Apr 1; [Epub ahead of print] Lambert, J.D., Lee, M-J., Diamond, L., Ju, J., Hong, J., Bose, M., Newmark, H.L., and Yang, C.S. Dose-dependent levels of epigallocatechin-3-gallate in human colon cancer cells and mouse plasma and tissue. Drug Metab. Disp. 34: 8-11, 2006. Yang, C.S., Lambert, J.D., Hou, Z., Ju, J., Lu, G., and Hao, X. Molecular targets for the cancer preventive activity of tea polyphenols. Mol. Carcinog. 45: 431-435, 2006. Yang, C.S. , Sang, S., Lambert, J.D., Hou, Z., Ju, J., and Lu, G. Possible mechanisms of the cancer-preventive activities of green tea. Mol. Nutr. Food Res., 50: 170-175, 2006. Landau, J.M., Lambert, J.D., and Yang, C.S. Green tea. Nutr. Oncol. Chapter 35: 597-606, 2006. Schinazi, R.F., Hernández-Santiago, B.L. & Hurwitz, S.J. 2006. Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses Antiviral Res. (In press). Vilaseca I, Chen AY, Backscheider AG. Long-term quality of life after total laryngectomy. Head Neck 2006;28:313-320. Fowler Z, Chen AY, Muller S, Johnstone PJ. Factors influencing long-term survival following salvage total laryngectomy after initial radiotherapy or conservative surgery. Head Neck 2006;28(2):99-106. Beningfield A, Nehus E, Chen AY, Yellin S. Pseudoaneurysm of the internal carotid artery after retropharyngeal abscess. Otolaryngol Head Neck Surg 2006;134(2):338-9. Chen A , Vilaseca I, Hudgins P, Schuster D, Halkar R. PET-CT vs. contrast-enhanced CT: What is the role for each after chemoradiation for advanced oropharyngeal cancer? Head Neck 2006;28(6):487-95. Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., Ove, R., Kies, M. S., Baselga, J., Youssoufian, H., Amellal, N., Rowinsky, E. K., and Ang, K. K. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med, 354: 567-578, 2006. |
|
Zhang, X., Su, L., Pirani, A., Zhang, H., Shin, D. M., Gernert, K.M., Chen, Z(G). Understanding metastatic SCCHN cells from unique genotypes to phenotypes with the aid of an animal model and DNA microarray analysis. Clin Exp Metastasis, 23:209-222, 2006. Penner CR, Muller S. Head and neck amyloidosis: a clinicopathologic study of 15 cases. Oral Oncology 42: 409-411, 2006. Wang L, Wang J, Sun S-Y, Rodriguez M, Yue P, Jang SJ, Mao L. A novel DNMT3B subfamily, DeltaDNMT3B, is the predominant form of DNMT3B in non-small cell lung cancer. Int J Oncol, 29:201-7, 2006. Liu XG, Yue P, Schonthal AH, Khuri FR, Sun S-Y. c-FLIP downregulation contributes to celecoxib-induced apoptosis in human lung cancer cells. Cancer Res, 66:11115-9, 2006. Saba N , Khuri, F, Shin D. Targeting the Epidermal Growth Factor Receptor, Trials in Head and Neck and Lung Cancer, Oncology, 2006, Feb . S.W. Han , F. R. Khuri, J Roman. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of the Akt/mTOR/S6K and inactivation of LKB1/AMPK signal pathways. Cancer Res. 66: 315-23, 2006. Beningfield A, Nehus E, Chen AY, Yellin S. Pseudoaneurysm of the internal carotid artery after retropharyngeal abscess. Otolaryngol Head Neck Surg 2006;134(2):338-9. Henderson , J.M., Boyer, T.D., Kutner, M.H. , Galloway, J.R., Rikkers, L.F., Jeffers, L.J., Abu-Elmagd, K., Connor, J.: DIVERT Study Group. Distal Slenorenal Shunt versus Transjugular Intrahepatic Portal Systematic Shunt for Variceal Bleeding: A Randomized Trial. Gastroenterology, 130(6):1643-1651, 2006. Wolf SL, O’Grady M, Easley KA, Guo Y, Kressig RW, Kutner MH. The influence of intense tai chi training on physical performance and hemodynamic outcomes in transitionally frail adults. Journals of Gerontology: Medical Sciences Series A – Biological Sciences & Medical Sciences, 61(2): 184-189, 2006. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones C, Sur R, Raben D, Jassem J, Ove R, Kies M, Baselga J, Amellal N, Rowinsky EK, Ang KK. Cetuximan plus radiotherapy for locally advanced squamous cell carcinoma of head and neck, New Eng J Med, 354: 567-579, 2006. Saba NF , Chen ZG, Shin DM, Vascular targeting and therapeutics for head and neck cancer. Am J Cancer:5 (1):7-18, 2006. Lippman SM, Lee JJ, Matin JW, El-Naggar, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA, Zhou Z, Papadimitrakopoulou V, Khuri FR, Clayman GL, Hittleman WN, Hong WK, Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia, Clin Cancer Res, 12(10): 3109-3114, 2006. Liu X, Yue P, Schonthal AH, Khuri FR, Sun SY. Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells. Cancer Research. 66(23):11115-11119, 2006. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri FR, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. Journal of Clinical Oncology. 24(25): 4163-4169, 2006. Marcus AI, O’Brate AM, Buey RM, Zhou J, Thomas S, Khuri FR, Andreu JM, Díaz F, Giannakakou P. Farnesyltransferase inhibitors reverse taxane resistance. Cancer Research. 66(17): 8838-8846, 2006. Kim KB, Faderl S, Hwang CS, Khuri FR. Chronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literature. Journal of Clinical Pharmacy and Therapeutics. 31, 401-406, 2006. Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA Jr, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittelman WN, Hong WK, Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. Clinical Cancer Research. 12(10): 3109-3114, 2006. Oh SH, Kim WY, Kim JH, Younes MN, El-Naggar AK, Myers JN, Kies M, Cohen P, Khuri F, Hong WK, Lee HY. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clinical Cancer Research. 12(2):653-61, 2006 Khuri FR , Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong WK. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. Journal of the National Cancer Institute 98(7), 441-450, 2006. Han S , Khuri FR , Roman J . Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Research. 66(1): 315-23, 2006 Sinha R, Kim G, Nie S, Shin DM: Nanotechnology in Cancer Therapeutics: Bioconjugated Nanoparticles for Drug Delivery, Mol Cancer Ther 5:1909-1917, 2006. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Evans AA, Blot WJ, Chow W, Blount PL, Maley CC, Wang KK , Lee JJ, Dubinett SM, Engstrom PF, Meyskens Jr. FL, Ransohoff DF, Hawk ET, Levin B, Nelson WG, and Hong WK. Progress in chemoprevention drug development: The promise of molecular biomarkers for cancer prevention and treatment and prevention of intraepithelial neoplasia (IEN), Clin Cancer Res 12:3661-3697, 2006. Khuri FR , Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong WK. Randomized phase III trail of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Nat Cancer Ins, 98: 441-50, 2006. Saba , N. F ., Chen, Z (G),Shin, D. M. Vascular targeting and therapeutics for head and neck cancer. Am J Cancer, 5:7-18, 2006. Tighiouart, M., Rogatko, A. Dose Finding in Oncology – Parametric Methods. In: Dose Finding in Drug Development. Ting, Naitee (Ed.). Springer, pp. 59-72, 2006. Tighiouart, M., Rogatko, A. Dose Escalation with Overdose Control. In: Statistical Methods for Dose-Finding Experiments. Sylvie, Chevret (Ed.). Wiley, pp. 173-188, 2006. Vilaseca I, Chen A, Burridge A. Long term quality of life for laryngectomees, Head Neck, Head Neck 2006;28:313-320.Chen AY, Schrag NM , Hao Y, Stewart A, Ward E. Changes in treatment of advanced oropharyngeal cancer 1985-2001. Laryngoscope. Sinha, R., Kim, G., Nie, S., Shin, D.M. Nanotechnology in Cancer Therapeutics: Bioconjugated Nanoparticles for Drug Delivery. Mol Cancer Ther.
Yang, L., Mao, H., Cao, Z., Wang, A.Y., Peng, X., Wang, X., Karna, P., Adams, A., Yuan, Q.A., Staley, C.A., Wood, W.C., Nie, S, and Gao, X. Development of peptide-conjugated Superparamagnetic Iron Oxide (IO) Nanoparticles for in vivo Imaging and Therapy of Pancreatic Cancer. Proceeding of NSTI Nanotechnology Cancer Nano 2006, in press Chen AY, Schrag NM, Hao Y, Flanders D, Kepner J, Stewart A, Ward E. Changes in treatment of advanced laryngeal cancer 1985-2001. Otolaryngology-Head and Neck Surgery, in press.
|
||
| Last update: July 31st, 2008 by Robert Fu & Edwin Shin |
||